North Carolina is currently home to 2641 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Durham, Charlotte, Winston-Salem and Chapel Hill. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Post Approval Study - Evaluate the Long-Term Safety and Effectiveness of the WEB Device
Recruiting
A prospective, multicenter, single arm, interventional study. The target patient population for this study are adult subjects with WNBAs of the anterior and posterior intracranial circulation. The primary effectiveness outcome of the study is adequate intracranial aneurysm occlusion on the 1 year angiogram as adjudicated by a core laboratory.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/13/2025
Locations: Duke University, Durham, North Carolina
Conditions: Wide Neck Bifurcation Intracranial Aneurysms
G7 Acetabular System With Vivacit-E or Longevity Liner PMCF Study
Recruiting
The main objectives of this study are to confirm the long-term safety, performance, and clinical benefits of the G7 Acetabular Shells when used with the Vivacit-E and Longevity HXLPE liners and instrumentation in primary and revision total hip arthroplasty.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/13/2025
Locations: Duke University Medical Center, Durham, North Carolina
Conditions: Total Hip Arthroplasty, Degenerative Joint Disease of Hip, Avascular Necrosis of Hip, Rheumatoid Arthritis of Hip, Osteoarthritis, Hip, Osteoarthritis of Hip, Fractures, Hip, Fracture of Hip
Remote Hypertension Management for Black Patients
Recruiting
This study will compare two approaches for managing hypertension in Black patients with uncontrolled blood pressure (BP). One approach will include home BP telemonitoring supported by a pharmacist and a community health worker. The other approach will include usual clinic-based care along with a home BP monitor and routine care.
Gender:
ALL
Ages:
Between 21 years and 85 years
Trial Updated:
06/12/2025
Locations: Wake Forest University Health Sciences, Winston-Salem, North Carolina
Conditions: Uncontrolled Hypertension
RECOVER-ENERGIZE Platform Protocol_Appendix A (Exercise Intolerance)
Recruiting
This is a platform protocol designed to be flexible so that it is suitable for a range of interventions and settings within diverse health care systems and community settings with incorporation into clinical COVID-19 management programs and treatment plans if results achieve key study outcomes. This protocol is a prospective, multi-center, multi-arm, randomized, controlled platform trial evaluating interventions to address and improve exercise intolerance and post-exertional malaise (PEM) as ma... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/12/2025
Locations: All sites listed under NCT06404047, Durham, North Carolina
Conditions: Long COVID, Long Covid19, Long Covid-19
SRG-514 Administered Intraoperatively to Patients Undergoing Breast-conserving Cancer Surgery
Recruiting
This is a multicenter, first-in-human (FIH), open label, Phase 1 dose escalation and recommended Phase 2 dose (RP2D) extension trial with a primary objective to define the RP2D of SRG-514 when administered intraoperatively to patients undergoing breast-conserving cancer surgery. SRG-514 will be investigated utilizing a 3+3 convention dose escalation cohorts.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/12/2025
Locations: Duke Cancer Center, Durham, North Carolina
Conditions: Breast Cancer
A Study of FX-909 in Patients With Advanced Solid Malignancies, Including Advanced Urothelial Carcinoma
Recruiting
The goal of this clinical trial is to study the safety and tolerability in all advanced solid tumors, including advanced urothelial carcinoma. The main question\[s\] it aims to answer are: * Is FX-909 safe and tolerable * What is the right dose level for patients Participants will be asked to take FX-909 daily , in tablet form and record any outcomes from taking the drug. Participants will also be asked to return for multiple site visits for various blood tests and to collect blood and tumor... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/12/2025
Locations: UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina
Conditions: Advanced Solid Tumors Cancer, Advanced Urothelial Carcinoma, Oral Drug Administration, Open Label
A Study to Evaluate PEEL-224 in Patients With Advanced Solid Tumors
Recruiting
This is a first-in-human, dose escalation, repeat-dose, multi-center, open-label study evaluating safety, tolerability, PK, and preliminary antitumor activity of PEEL-224 in patients with advanced solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/12/2025
Locations: Carolina BioOncology Institute, Huntersville, North Carolina
Conditions: Advanced Solid Tumor
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
Recruiting
This is a first in human, open-label, multi-center Phase 1 / 2 study to evaluate the safety, tolerability, and initial efficacy of AU-007 in patients with advanced solid tumors. AU-007 will be administered either as a monotherapy, or in combination with a single loading dose of aldesleukin, or with both AU-007 and aldesleukin given every 2 weeks (Q2w). Once the recommended phase 2 dose (RP2D) of AU-007 plus aldesleukin was determined, (AU-007 Q2w plus a single loading dose of aldesleukin), AU-00... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/12/2025
Locations: Carolina Biooncology Institute, Huntersville, North Carolina
Conditions: Advanced Solid Tumor, Metastatic Cancer, Cutaneous Melanoma, Non-Small Cell Lung Cancer
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
Recruiting
This is a first-in-human Phase 1a/1b multicenter, open-label study designed to evaluate the safety and anti-cancer activity of NX-5948 in patients with advanced B-cell malignancies.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/12/2025
Locations: Duke University Medical Center, Durham, North Carolina
Conditions: Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), Diffuse Large B Cell Lymphoma (DLBCL), Follicular Lymphoma (FL), Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL), Waldenstrom Macroglobulinemia (WM), Primary Central Nervous System Lymphoma (PCNSL), Secondary Central Nervous System Lymphoma (SCNSL)
APOL1 Long-term Kidney Transplantation Outcomes Network (APOLLO)
Recruiting
The APOLLO study is being done in an attempt to improve outcomes after kidney transplantation and to improve the safety of living kidney donation based upon variation in the apolipoprotein L1 gene (APOL1). Genes control what is inherited from a family, such as eye color or blood type. Variation in APOL1 can cause kidney disease. African Americans, Afro-Caribbeans, Hispanic Blacks, and Africans are more likely to have the APOL1 gene variants that cause kidney disease. APOLLO will test DNA from ki... Read More
Gender:
ALL
Ages:
All
Trial Updated:
06/12/2025
Locations: Duke University, Durham, North Carolina
Conditions: Kidney Diseases, Kidney Failure, Kidney Disease, Chronic
DBT-P Treatment Study
Recruiting
The goal of this study is to find out if improving emotion regulation skills use during pregnancy reduces maternal stress and improves heart rate. The main questions it aims to answer are: * Does improving emotion regulation skills during pregnancy reduce stress and improve the ability to cope? * How is a participant's heart rate affected by their ability to control their emotions during pregnancy? Researchers will test the hypothesis that dialectical behavior therapy skills groups (DBT-P) wi... Read More
Gender:
FEMALE
Ages:
Between 18 years and 45 years
Trial Updated:
06/11/2025
Locations: Duke University, Durham, North Carolina
Conditions: Emotion Dysregulation
Optimizing Perioperative Analgesia to Lower Pain Following Cleft Palate Surgery
Recruiting
The purpose of this study is to compare the use of short acting opioids (fentanyl/hydromorphone) with long acting opioids (methadone) for pain control following cleft palate surgery in infants and young children.
Gender:
ALL
Ages:
Between 6 months and 4 years
Trial Updated:
06/11/2025
Locations: Duke University Medical Center, Durham, North Carolina
Conditions: Cleft Palate, Pain, Postoperative Care, Perioperative Care, Children